Charles Chen

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

D. Auclair, P. Vincent, G. Bollag, 2004, Cancer Research.

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

S. Wilhelm, M. Lynch, Christopher A. Carter, 2006, Cancer research.

Hepatocellular Carcinoma Model PLC / PRF / 5 Tumor Angiogenesis , and Induces Tumor Cell Apoptosis in Sorafenib Blocks the RAF / MEK / ERK Pathway , Inhibits

S. Wilhelm, M. Lynch, Christopher A. Carter, 2006 .

Receptor Tyrosine Kinases Involved in Tumor Progression Activity and Targets the RAF/MEK/ERK Pathway and BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor

D. Auclair, P. Vincent, G. Bollag, 2004 .

Anticancer Effects of Midazolam on Lung and Breast Cancers by Inhibiting Cell Proliferation and Epithelial-Mesenchymal Transition

E. So, Charles Chen, King-Chuen Wu, 2021, Life.

Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma

P. Vincent, Christopher A. Carter, Charles Chen, 2006, Cancer Chemotherapy and Pharmacology.

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

D. Auclair, P. Vincent, G. Bollag, 2004, Cancer Research.